welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
scientific articles

Celiprolol: A Unique Selective Adrenoceptor Modulator

key information

source: Cardiology in review

year: 2017

authors: Nawarskas JJ, Cheng-Lai A, Frishman WH

summary/abstract:

Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and is indicated for those uses in various countries around the world. In the United States, however, the proposed indication for this drug will be for the treatment of vascular type Ehlers-Danlos syndrome, a rare connective tissue disorder characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure, celiprolol may reduce the mechanical stress on collagen fibers within the arterial wall and be of benefit in patients with vascular type Ehlers-Danlos syndrome. The largest investigation of celiprolol in vascular Ehlers-Danlos syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol, therefore, represents a β-blocker that is unique from others in its class in both its pharmacology and clinical applications.

organization: College of Pharmacy, University of New Mexico, Albuquerque; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx; New York Medical College/Westchester Medical Center, Valhalla

DOI: 10.1097/CRD.0000000000000159

read more full text source

expertly curated content related to this topic